Latest / The Diagnostics & Lab Testing Business Brief
The Diagnostics & Lab Testing Business Brief — Monday, November 2, 2026
The Diagnostics & Lab Testing Business Brief — Monday, November 2, 2026
The business behind the tests. Today's developments shaping the diagnostics industry.
Tempus AI reports third-quarter 2026 results: total revenue $411.5 million (+23%), Diagnostics revenue $303.5 million (+20%) on oncology volume growth of 32%, MRD volume of ~12,000 tests (up 300%), Data & Applications revenue $108.1 million (+33%); Adjusted EBITDA $25.6 million; full-year 2026 revenue guidance raised to $1.60–$1.605 billion with Adjusted EBITDA of ~$65 million expected; pending Personalis acquisition has cleared…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.